Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Artrya Limited ( (AU:AYA) ) has provided an update.
Artrya Limited has made significant strides in its efforts to commercialize its coronary artery disease detection technology. The company is in the process of responding to the FDA’s feedback on its 510(k) application, with expectations of clearance by March 2025. Artrya has also successfully raised A$5 million to support its operations and strengthen its financial position. This funding will help sustain regulatory clearance efforts and future commercialization in the US. Additionally, the company is actively engaging with major healthcare systems in the US and is in negotiations with radiology groups in Australia, aiming to expand the adoption of its Salix® Coronary Anatomy product.
More about Artrya Limited
Artrya Limited is a medical technology company specializing in an AI platform designed to detect, diagnose, and manage coronary artery disease. The company focuses on commercializing its patented products, particularly targeting healthcare systems in the United States and radiology groups in Australia.
YTD Price Performance: 66.04%
Average Trading Volume: 134,678
Technical Sentiment Consensus Rating: Sell
For detailed information about AYA stock, go to TipRanks’ Stock Analysis page.
